New, tolerable γ-secretase inhibitor takes desmoid down a notch.

ABSTRACT: A phase I trial of PF-03084014, an oral reversible γ-secretase inhibitor, in solid tumor malignancies shows drug tolerability in patients. Evidence of Notch pathway inhibition was demonstrated in peripheral blood. A surprisingly high rate of response was seen in desmoid tumors, a rare but sometimes locally aggressive sarcoma.

SUBMITTER: Hughes DP 

PROVIDER: S-EPMC4306586 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature